Borderline ovarian tumors: A study of 100 cases

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15069-15069
Author(s):  
C. E. Taner ◽  
M. Oztekin ◽  
S. Mun ◽  
S. Sehirali ◽  
C. Büyüktosun ◽  
...  
Keyword(s):  
Early Stage ◽  
Young Patients ◽  
Disease Free Survival ◽  
Conservative Surgery ◽  
Ovarian Tumors ◽  
Histopathological Diagnosis ◽  
Early Stage Disease ◽  
Borderline Ovarian Tumors ◽  
Stage Disease ◽  
Fertility Sparing

15069 Background: The purpose of the study was to evaluate the patients with borderline ovarian tumors. Methods: Clinical features, treatment and survival status of 100 patients with borderline ovarian tumors were retrospectively evaluated between 1998 and 2005. Results: Mean age was 37.75 (Range: 15–72) years. 22 cases were in postmenapausal status. Histopathological diagnosis was serous, musinous, endometrioid and clear cell in 54%, 41%, 2%, 3% of the patients, respectively. 19 cases underwent restaging laparotomy. In 52 cases fertility sparing surgery was performed. 70 patients had stage IA, 8 patients had stage IB, 16 cases had stage IC, 2 cases had stage IIIA, 3 cases cases had stage IIIB and a case had stage IIIC disease. 22 cases were administered chemotherapy because of advanced stage disease. All cases were alive. 5 year disease free survival of 51 cases was 100%. Conclusions: Borderline ovarian tumors have excellent prognosis and conservative surgery can be performed in young patients with early stage disease. No significant financial relationships to disclose.

scholarly journals Sertoli-Leydig Cell Ovarian Tumors: Is Fertility or Endocrine-Sparing Surgery an Option upon Relapse?

2020 ◽  
Vol 13 (2) ◽  
pp. 935-940
Author(s):  
Stéphanie J. Seidler ◽  
Alexandre Huber ◽  
James Nef ◽  
Daniela E. Huber
Keyword(s):  
Leydig Cell ◽  
Early Stage ◽  
Young Patients ◽  
Hormonal Treatment ◽  
Conservative Surgery ◽  
Good Prognosis ◽  
Ovarian Tumors ◽  
Fertility Sparing ◽  
Bep Chemotherapy

Sertoli-Leydig cell ovarian tumors (SLCT) are rare ovarian tumors of the sex cord-stroma subset. Their incidence peaks in the second to third decade of life. Most SCLT are diagnosed at an early stage and have a good prognosis. Fertility-sparing surgery may thus be offered. Adjuvant chemotherapy may be indicated according to prognostic factors. However, outcome in relapsing SLCT is poor. There is no evidence supporting a best treatment option upon relapse, but most publications combine radical surgery, chemotherapy, and rarely radiotherapy. Two years after left adnexectomy for FIGO IA SLCT, a now 22-year-old patient presented with peritoneal recurrence without involvement of the remaining ovary and uterus. Since there is no evidence of a survival benefit in the literature of macroscopically healthy contralateral ovary ablation in relapse and hormonal replacement therapy is contraindicative, we consented to endocrine-sparing surgery with conservation of the contralateral ovary, followed by 3 cycles of BEP chemotherapy regimen. Our patient is disease-free 16 months after relapse diagnosis. Since recurrence of SLCT has a very poor prognosis and hormonal treatment is contraindicated, endocrine-sparing surgery for young patients with a normal contralateral ovary might be a legitimate option. This is one of the first reported cases of conservative surgery in SLCT recurrence, we therefore aimed to illustrate its management in a young patient with considerations of contraception, fertility- and then endocrine-sparing surgery, and quality of life.

Borderline ovarian tumors: Long-term survival and preservation of fertility.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15508-e15508
Author(s):  
Natasha Gercovich ◽  
Carlos Garcia Gerardi ◽  
Ernesto Gil Deza ◽  
Eduardo L. Morgenfeld ◽  
Edgardo G. J. Rivarola ◽  
...  
Keyword(s):  
Young Patients ◽  
Conservative Surgery ◽  
Ovarian Tumors ◽  
Population Characteristics ◽  
Borderline Tumor ◽  
Term Survival ◽  
Borderline Tumors ◽  
Borderline Ovarian Tumors ◽  
The Usa

e15508 Background: Borderline ovarian tumors, also called low-malignancy potential tumors, are infrequent tumors present predominantly in pre-menopause women. Their evolution after surgical treatment is generally very good. The main objective of this paper is to show the evolution of a group of borderline tumors treated at our institution. Methods: Between January 1, 2000 and January 1, 2010, 36 patients diagnosed with ovarian borderline tumors were examined by two independent pathologists, according to the guidelines established by the USA Association of Directors of Anatomic and Surgical Pathology. These patients were followed at IOHM and comprise this paper’s study group. Results: Population Characteristics: Mean Age: 41 years (Range: 20-85). Affected Ovary (Right: 17 pts; Left: 14 pts; Both: 5 pts). Pathology: Mucinous (17 pts), Serous (16 pts), Clear, Brenner and Endometroid Cells (1 pt each). Stages: IA (24 pts), IB (5 pts), IC (2pts), IIIA (4 pts), IIIC (1 pt). Five patients presented non-invasive peritoneal implants and three presented positive peritoneal liquid. All patients were surgically treated: 28 with total anexohisterectomy (TAH) and 8 with unilateral ooforectomy. No patient was given any chemotherapy or radiotherapy treatment. Four patients did not attend follow-up consultations and were lost after 4, 6, 12 and 29 months with no evidence of disease (NED). Thirty-two patients were followed bi-annually during the first five years and annually thereafter. One patient became pregnant after the surgery. All patients are alive and NED with an average follow up of 50 months (range: 29-133). Conclusions: 1) Although half the cases in the study were under 35 years old, there were 12 tumors present in patients over 50 years of age and 1 borderline tumor present in an 85 year old patient. 2) Surgically treated ovarian borderline tumors have a high chance of being curable without the need of chemotherapy or radiotherapy. 3) Conservative surgery in young patients allows a conservation of fertility, provided they are subject to an adequate follow-up.

Fertility-Sparing Surgery for Borderline Ovarian Tumors: Oncologic Safety and Reproductive Outcomes

2011 ◽  
Vol 21 (4) ◽  
pp. 640-646 ◽  
Author(s):  
Taejong Song ◽  
Chel Hun Choi ◽  
Hwang Shin Park ◽  
Min-Kyu Kim ◽  
Yoo-Young Lee ◽  
...  
Keyword(s):  
Young Patients ◽  
Ovarian Tumors ◽  
Reproductive Outcomes ◽  
Recurrence Rates ◽  
Main Site ◽  
Oncological Safety ◽  
Borderline Ovarian Tumors ◽  
Fertility Sparing Surgery ◽  
Initial Surgery ◽  
Fertility Sparing

Introduction:To evaluate the oncological safety and reproductive outcomes of patients with borderline ovarian tumors (BOTs) treated with fertility-sparing surgery.Methods:Patients with BOTs who underwent radical or fertility-sparing surgery between 1997 and 2009 were identified from an institutional database. The recurrence rates were compared between the 2 surgery groups. To compare the reproductive outcomes, all patients who underwent fertility-sparing surgery were interviewed by telephone.Results:One hundred forty-three patients underwent radical surgery, and 155 patients underwent fertility-sparing surgery. After a median interval of 38 months from the initial surgery (range, 10-77 months), 19 patients had a recurrence. The recurrence rate was similar in the radical and fertility-sparing surgery groups (4.9% and 7.7%, respectively;P= 0.280). In the fertility-sparing surgery group, however, the main site of recurrence was the remaining ovary that was successfully salvaged with a second round of fertility-sparing surgery. Of 51 patients who attempted to conceive, 45 patients (88.2%) were successful and resulted in 54 term deliveries.Conclusions:Fertility-sparing surgery for BOTs is safe and can result in future pregnancies, suggesting that such surgery should be considered for young patients who desire preservation of fertility.

Induction of matric metalloprotease-7 is common in mucinous ovarian tumors including early stage disease

2000 ◽  
Vol 17 (1) ◽  
pp. 52-58 ◽  
Author(s):  
K Shigemasa ◽  
H Tanimoto ◽  
K Sakata ◽  
N Nagai ◽  
TH Parmley ◽  
...  
Keyword(s):  
Early Stage ◽  
Ovarian Tumors ◽  
Early Stage Disease ◽  
Stage Disease ◽  
Mucinous Ovarian Tumors

scholarly journals Oncologic and obstetric outcomes of fertility-sparing surgery for borderline ovarian tumors in women of reproductive age: a retrospective cohort study

2020 ◽  
Author(s):  
Rui Sun ◽  
Chengyan Luo ◽  
Yi Jiang ◽  
Shulin Zhou ◽  
Yicong Wan ◽  
...  
Keyword(s):  
Live Birth ◽  
Odds Ratio ◽  
Disease Free Survival ◽  
Ovarian Tumors ◽  
Obstetric Outcomes ◽  
Free Survival ◽  
Borderline Ovarian Tumors ◽  
Kaplan Meier ◽  
Fertility Sparing ◽  
Disease Free

Abstract Objective To retrospectively evaluate the oncologic and obstetric outcomes of fertility-sparing surgery (FSS) for borderline ovarian tumors(BOT). Methods 132 patients with borderline ovarian tumors were divided into the incompletely staging surgery (ISS) group and the completely staging surgery (CSS) group. The overall survival and disease-free survival curves were determined using the Kaplan–Meier method. The Cox proportional hazards method was used to assess the association between the variables and live birth and multivariate analysis to identify the independent associations. Results Chi-square and Kaplan-Meier analyses showed no significant differences in overall survival between the two groups (p = 1.000 and p = 0.716, respectively). The CSS group had fewer relapses and longer disease-free survival than ISS (p = 0.003). There was no statistical difference in live birth rate between two groups (crude odds ratio = 0.885, 95%CI 0.411–1.903, p = 0.755; adjusted odds ratio = 0.848, 95%CI 0.366–1.963, p = 0.700). Age was the only independent risk factor for live birth (adjusted odds ratio = 0.902, 95%CI 0.823–0.988, p = 0.027). Mean live birth intervals after FSS was 31.86 ± 19.325 months. Conclusions CSS significantly increased the disease-free survival time of BOT and reduced the relapse risk. However, CSS had a slightly negative and statistically insignificant association with live birth.

Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004

2007 ◽  
Vol 17 (2) ◽  
pp. 342-349 ◽  
Author(s):  
H. F. Wong ◽  
J. J.H. Low ◽  
Y. Chua ◽  
I. Busmanis ◽  
E. H. Tay ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Early Stage ◽  
Conservative Surgery ◽  
Figo Stage ◽  
Ovarian Tumors ◽  
Reproductive Age ◽  
Time To Recurrence ◽  
Fertility Sparing ◽  
Significant Difference ◽  
Oncology Unit

Borderline ovarian tumors account for 15% of epithelial ovarian cancers and are different from invasive malignant carcinoma. Majority are early stage, occurring in women in the reproductive age group, where fertility is important. We reviewed retrospectively 247 such cases treated at the Gynaecological-Oncology Unit, KK Women's and Children's Hospital, between January 1991 and December 2004. The mean age was 38 years (16–89 years). Majority of the cases (92%) were FIGO stage I (Ia, 75%; Ib, 1%; and Ic, 16%). Seven (3.5%) patients were diagnosed as having stage II disease, six (2.5%) as stage IIIa, two (1%) as stage IIIb, and four (2%) as stage IIIc. Histological origin was as follows: mucinous (68%), serous (26%), endometrioid (2.6%), and clear cell (1.2%). Primary surgical procedures undertaken were as follows: hysterectomy with bilateral salpingo-oophorectomy (52%), unilateral salpingo-oophorectomy (33%), or ovarian cystectomy (15%). Adjuvant chemotherapy was administered in 13 patients (5.2% of cases), of which 4 patients were given chemotherapy only because of synchronous malignancies. There were six recurrences (2.4% of cases). Overall mean time to recurrence was 59 months. Recurrence rate for patients who underwent a primary pelvic clearance was 1.6% compared to fertility-sparing conservative surgery (3.3%; although P= 0.683). No significant difference was noted in recurrence and mortality between staged versus unstaged procedures. The overall survival rate was 98.0%. There were a total of five deaths (2.8%): three (1.5%) from invasive ovarian/peritoneal carcinoma and two from synchronous uterine malignancies. It appears that surgical resection is the mainstay of treatment, with conservative surgery where fertility is desired or pelvic clearance if the family is complete. Surgical staging is important to identify invasive extraovarian implants that portend an adverse prognosis. The role of adjuvant chemotherapy is not established.

Prevalence of delay to seeking medical attention in patients with synovial sarcoma and association with inferior outcomes.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e23556-e23556
Author(s):  
Tiffany Seto ◽  
Meena Song ◽  
Elisabeth Russell ◽  
Danny Sam ◽  
Minggui Pan
Keyword(s):  
Synovial Sarcoma ◽  
Metastatic Disease ◽  
Median Duration ◽  
Early Stage ◽  
Young Patients ◽  
Medical Attention ◽  
Early Stage Disease ◽  
Palpable Mass ◽  
Presenting Symptoms ◽  
Stage Disease

e23556 Background: Synovial sarcoma is an aggressive soft tissue sarcoma that predominantly affects young patients with high rate of relapse and mortality. Systemic study of patients’ presenting symptoms and possible delay of seeking medical attention is lacking. Methods: We retrospectively reviewed the electronic records of all patients diagnosed with synovial sarcoma from 2005 to 2016 within Kaiser Permanente Northern California to identify the pattern of presenting symptoms and its correlation with outcomes. Results: Of the 77 patients with synovial sarcoma, 64 had early stage disease and 13 had metastatic disease at diagnosis, with median age at diagnosis of 47 years. Anatomically, 48 patients had primary disease at the extremity, 12 trunk, and 17 visceral. Median duration of follow up is 40 months. The median time from symptom to first medical appointment (TTM) is 3 months (range 0.1 to 180 months). Nine out of 13 patients who presented with metastatic disease were visceral primary. For the 60 patients with an extremity/trunk primary, patients who presented with pain without a palpable mass had a median duration of TTM of 12 months, compared to the TTM of 3 months for patients who presented with a palpable mass. The relapse rate (RR) and disease-free survival (DFS) for patients with an extremity/trunk primary who presented with pain but without a palpable mass were significantly worse when compared to patients who presented with a palpable mass (RR 50% vs. 26.5%, and DFS 27 vs. 42.5 months, p < 0.005). TTM was inversely correlated with DFS for the 64 cases with early stage disease and for the 60 cases with extremity/trunk primary (p < 0.00000001). Of the 11 patients with a foot primary, a similar pattern of TTM and DFS was also observed. Conclusions: Patients with synovial sarcoma who presented with pain but without a palpable mass had longer TTM, worse DFS and higher RR compared to patients who presented with a palpable mass. Longer TTM was associated with worse DFS.

High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1

2008 ◽  
Vol 117 (1) ◽  
pp. 131-140 ◽  
Author(s):  
Biyun Qian ◽  
Dionyssios Katsaros ◽  
Lingeng Lu ◽  
Mario Preti ◽  
Antonio Durando ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Disease Free Survival ◽  
Early Stage Disease ◽  
Free Survival ◽  
Stage Disease ◽  
Disease Free ◽  
Tgf Β1

scholarly journals Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia

Genes ◽  
2020 ◽  
Vol 11 (6) ◽  
pp. 686
Author(s):  
Sandra Ballester ◽  
Begoña Pineda ◽  
Patricia Rodrigues ◽  
Eduardo Tormo ◽  
María José Terol ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Protective Effect ◽  
Genetic Risk ◽  
Early Stage ◽  
Disease Free Survival ◽  
Population Based ◽  
Lymphocytic Leukemia ◽  
Early Stage Disease ◽  
Stage Disease ◽  
Angiogenesis Process

Angiogenesis process contributes to the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL) being the levels of VEGFA and bFGF higher in patients than in healthy controls. Our aim was to evaluate the implication of angiogenesis factors genetic variants in the predisposition to B-CLL and their association with clinical factors and survival. We performed a population-based case-control study in 224 Spanish B-CLL patients and 476 healthy randomly selected controls to evaluate susceptibility to developing B-CLL. Six polymorphisms were evaluated: rs1109324, rs1547651, rs3025039 (+936 C>T), rs833052 of the VEGFA gene, rs1449683 (c.233C>T) of the bFGF gene and (−710 C>T) of the VEGFR1 gene. The association between clinical parameters and patient outcome was analyzed. Carriers of the CT/TT variants of rs3025039 showed a significant protective effect against developing B-CLL. The CT/TT variants of rs1449683 show a tendency towards the development of the disease and the same variants associated significantly with higher genetic risk and with reduced disease free survival. Moreover, the association persisted in the early-stage disease subgroup. Our study provides evidence of the protective effect of the T/- rs3025039 VEGFA variant against B-CLL development and the association of CT/TT variants of the rs1449683 bFGF gene with genetic risk and an adverse survival.

Sign in / Sign up

Export Citation Format

Share Document